Literature DB >> 4056530

[Establishment and characterization of a cell line derived from mucinous cystadenocarcinoma of human ovary].

Y Kidera, T Yoshimura, Y Ohkuma, T Iwasaka, H Sugimori.   

Abstract

A human tumor cell line MCAS, which was derived from mucinous cystadenocarcinoma of the ovary, was established. The tissue specimen was obtained on December 1, 1983 and the culture was maintained in Ham's F-12 medium supplemented with 20% fetal calf serum. Continuous growth made possible cell transfer every 3-5 days and the seventy-third passage was achieved on August 15, 1984. This cell line has the following characteristics. The doubling time of the MCAS cell line was 27 hours and the saturation density was 5.1 X 10(4)/cm2. The cultured cells appeared monolayer and the cellular arrangement was a pavement-like pattern. Rather large cells with vacuoles in the cytoplasm appeared in the confluent state and PAS staining proved to be positive specifically in these large cells. A chromosomal analysis revealed a peritetraploid tendency. By heterotransplantation of MCAS cells to the nude athymic mouse, the tumor developed and had both cystic and solid components. The cystic content was mucinous. Histopathological diagnosis of the tumor was papillary adenocarcinoma and alcian blue staining was positive. The characteristics of the original mucinous cystadenocarcinoma have been precisely maintained in this cell line.

Entities:  

Mesh:

Year:  1985        PMID: 4056530

Source DB:  PubMed          Journal:  Nihon Sanka Fujinka Gakkai Zasshi        ISSN: 0300-9165


  8 in total

1.  Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.

Authors:  Sojiro Sato; Yoichi Kobayashi; Yoshiaki Okuma; Haruhiro Kondo; Yosuke Kanishi; Kaoru Saito; Kazusige Kiguchi
Journal:  Hum Cell       Date:  2002-09       Impact factor: 4.174

2.  Epidermal growth factor modulates claudins and tight junctional functions in ovarian cancer cell lines.

Authors:  Marie Ogawa; Takashi Kojima; Masayuki Someya; Kazuaki Nomura; Akira Takasawa; Masaki Murata; Satoshi Tanaka; Tsuyoshi Saito; Norimasa Sawada
Journal:  Histochem Cell Biol       Date:  2012-04-29       Impact factor: 4.304

3.  Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines.

Authors:  Yoshiaki Okuma; Kazushige Kiguchi; Yutaka Koshitaka; Asami Okamura; Isamu Ishiwata; Haruhiro Kondo; Bunpei Ishizuka; Mamoru Tadokoro
Journal:  Hum Cell       Date:  2003-09       Impact factor: 4.174

4.  Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).

Authors:  I Fukazawa; N Inaba; Y Ota; N Sato; S Shirotake; H Iwasawa; S Sekiya; H Takamizawa; N Suzuki; H Tokita
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

5.  SNOSite: exploiting maximal dependence decomposition to identify cysteine S-nitrosylation with substrate site specificity.

Authors:  Tzong-Yi Lee; Yi-Ju Chen; Tsung-Cheng Lu; Hsien-Da Huang; Yu-Ju Chen
Journal:  PLoS One       Date:  2011-07-15       Impact factor: 3.240

6.  Functional role of the Tau protein in epithelial ovarian cancer cells.

Authors:  Aisa Yamauchi; Asami Kobayashi; Hiroe Oikiri; Yoshihito Yokoyama
Journal:  Reprod Med Biol       Date:  2017-03-20

Review 7.  Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine.

Authors:  Christine Yee; Kristie-Ann Dickson; Mohammed N Muntasir; Yue Ma; Deborah J Marsh
Journal:  Front Bioeng Biotechnol       Date:  2022-02-10

8.  Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.

Authors:  Eniko Papp; Dorothy Hallberg; Gottfried E Konecny; Daniel C Bruhm; Vilmos Adleff; Michaël Noë; Ioannis Kagiampakis; Doreen Palsgrove; Dylan Conklin; Yasuto Kinose; James R White; Michael F Press; Ronny Drapkin; Hariharan Easwaran; Stephen B Baylin; Dennis Slamon; Victor E Velculescu; Robert B Scharpf
Journal:  Cell Rep       Date:  2018-11-27       Impact factor: 9.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.